Sharon A. Chung, MD, MAS, director of the vasculitis clinic at the University of California, San Francisco, served as the principal investigator of the overall vasculitis guideline effort and talks about the process here.
The ACR/Vasculitis Foundation Release Three New Guidelines for Treatment of Vasculitis
ATLANTA—The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of about 20 rare diseases that have inflammation of blood vessels in common, which can restrict blood flow and damage vital organs. The three guidelines cover…
The 2020 ACR Review Course: Key Issues Rheumatologists Face
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
10 Clinical Insights from Rheumatology Top Secrets & Pearls
In this ACR Convergence session, Jason R. Kolfenbach, MD, & John H. Stone, MD, MPH, shared clinical insights about rheumatic diseases.
A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
Update on the Management of Takayasu Arteritis
A rare form of large vessel vasculitis, Takayasu arteritis persents with no clear patterns, with patients experiencing vascular symptoms, as well as such systemic symptoms as fever and weight loss. A systematic literature review found evidence to guide rheumatologists in monitoring and treating their patients with Takayasu arteritis…
Malignancy Risk Varies with Treatment in Systemic Necrotizing Vasculitis
NEW YORK (Reuters Health)—The risk of malignancy in patients with systemic necrotizing vasculitis varies according to the treatment received, according to an analysis of five randomized controlled trials. Previous studies reported an increased risk of malignancy in patients with systemic necrotizing vasculitis, and a more recent study from the European Vasculitis Study Group, based on…
FDA Approves Rituximab for Children with GPA & MPA
Intravenous rituximab can now be used to treat pediatric patients with GPA and MPA as young as two years old…
Stay the Course: How to Maintain Remission in Vasculitis
MADRID—During the 2019 European Congress of Rheumatology (EULAR), held June 12–15, speakers addressed the complexity of vasculitis in a Challenges in Clinical Practice session titled, How to Maintain Remission in Vasculitis. Although vasculitis appears in many varieties, one commonality exists among these related yet distinct conditions: When there is vital organ or systemic involvement, disease…
Large Vessel Vasculitis Outcome Measures: An Update from OMERACT
In ongoing work to validate data-driven outcome tools for clinical investigation in large vessel vasculitis, an international team of rheumatologists from the Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group has published a report on subclinical disease activity and patient perspectives on therapy response…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »